Vaxcyte (PCVX) Receivables (2021)

Vaxcyte (PCVX) has reported Receivables for 4 consecutive years, with $17.9 million the latest figure, recorded in Q3 2024.

• In Q3 2024, Receivables rose 235.69% year-over-year to $17.9 million; the TTM figure through Sep 2024 stood at $17.9 million (up 235.69% YoY), while the FY2023 annual figure was $3.6 million, down 6.96% from the prior year.
• Receivables grew to $17.9 million in Q3 2024 per PCVX's latest filing, from $8.5 million in the prior quarter.
• Across five years, Receivables topped out at $17.9 million in Q3 2024 and bottomed at $3.6 million in Q4 2023.
• Historically, Receivables has averaged $7.5 million across 4 years, with a median of $5.3 million in 2023.
• Annual changes were most pronounced in 2023 — Receivables slipped 6.96% — and 2024, when it soared 235.69%.
• Vaxcyte's Receivables stood at $5.0 million in 2021, then declined by 22.46% to $3.9 million in 2022, then slipped by 6.96% to $3.6 million in 2023, then soared by 395.48% to $17.9 million in 2024.
• Business Quant data shows PCVX's Receivables at $17.9 million in Q3 2024, $8.5 million in Q2 2024, and $8.1 million in Q1 2024.